Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
Sanjay Kalra, A G Unnikrishnan, Manash Baruah and 2 more
Indian Journal of Endocrinology and Metabolism · 2017
doi:10.4103/ijem.ijem_184_17 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.